Quadrivalent Human Papillomavirus Vaccine
Open Access
- 1 September 2007
- journal article
- review article
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 45 (5), 609-617
- https://doi.org/10.1086/520654
Abstract
The lifetime risk of human papillomavirus (HPV) infection exceeds 50%. HPV infection causes >550,000 cases of cervical and anogenital cancer worldKeywords
This publication has 36 references indexed in Scilit:
- Model for Assessing Human Papillomavirus Vaccination StrategiesEmerging Infectious Diseases, 2007
- High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-upBritish Journal of Cancer, 2006
- Vulvar Intraepithelial NeoplasiaObstetrics & Gynecology, 2005
- Optimization and Validation of a Multiplexed Luminex Assay To Quantify Antibodies to Neutralizing Epitopes on Human Papillomaviruses 6, 11, 16, and 18Clinical and Vaccine Immunology, 2005
- Human Papillomavirus Vaccines and Prevention of Cervical CancerAnnual Review of Medicine, 2004
- Epidemiologic Classification of Human Papillomavirus Types Associated with Cervical CancerNew England Journal of Medicine, 2003
- Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysisBritish Journal of Cancer, 2003
- High incidence of cervical human papillomavirus infection in women during their first sexual relationshipBJOG: An International Journal of Obstetrics and Gynaecology, 2002
- Human Papillomavirus Testing for Triage of Women With Cytologic Evidence of Low-Grade Squamous Intraepithelial Lesions: Baseline Data From a Randomized TrialJNCI Journal of the National Cancer Institute, 2000
- JUVENILE LARYNGEAL PAPILLOMATOSIS IN A PEDIATRIC POPULATION: A Clinicopathologic StudyPediatric Pathology & Laboratory Medicine, 1997